文献速递药物不良反应与药物警戒

学术泛欧临床试验中集中式药物警戒系统的实施:EU-Response与conect4children联盟经验

Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.
PubMed 文献 · Br J Clin Pharmacol · 2023-02-08

学术申办方在多国临床试验中建立高质量药物警戒系统比企业更具挑战。Inserm-ANRS MIE药物警戒部门在覆盖19国的两个欧洲联盟中实施集中式药物警戒系统,包括统一安全流程、建立本地安全官网络和集中安全活动。EU-Response四项试验共报告1312例严重不良事件,c4c报告83例,该系统实现了对安全数据的全面控制和多国监管合规。

要点

  • 集中式药物警戒系统通过统一关键流程和本地安全官网络,帮助学术申办方在多国试验中实现监管合规。
  • EU-Response四项试验共处理1312例严重不良事件,c4c处理83例,均录入统一数据库。
  • 该系统可复用,为多个学术申办方建设药物警戒能力。

核心结论

  • 集中式药物警戒系统可帮助学术申办方在多国临床试验中高效管理安全数据并满足各国监管要求。

研究设计与样本

  • Inserm-ANRS MIE药物警戒部门在conect4children(儿科研究)和EU-Response(Covid-19平台试验)两个泛欧联盟的19个参与国中实施集中式药物警戒系统。
  • 该系统包括统一复杂安全流程的关键程序、建立本地安全官网络和集中所有安全活动。

主要发现

  • EU-Response的四项试验中共有1312例严重不良事件(SAE)。
  • c4c的四项试验中共有83例严重不良事件(SAE)。
  • 统一数据库处理SAE保证了对安全数据的全面控制和风险-获益比的持续评估。
  • 本地安全官网络促进了多国间高效的监管合规。

临床怎么用

  • 学术申办方可通过委托集中式药物警戒系统来管理多国试验的安全工作。
  • 建立本地安全官网络有助于应对欧洲各国异质性要求并实现高效沟通。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Setting-up a high quality, compliant and efficient pharmacovigilance (PV) system in multi-country clinical trials can be more challenging for academic sponsors than for companies. To ensure the safety of all participants in academic studies and that the PV system fulfils all regulations, we set up a centralized PV system that allows sponsors to delegate work on PV. This initiative was put in practice by our Inserm-ANRS MIE PV department in two distinct multinational European consortia with 19 participating countries: conect4children (c4c) for paediatrics research and EU-Response for Covid-19 platform trials. The centralized PV system consists of some key procedures to harmonize the complex safety processes, creation of a local safety officer (LSO) network and centralization of all safety activities. The key procedures described the safety management plan for each trial and how tasks were shared and delegated between all stakeholders. Processing of serious adverse events (SAEs) in a unique database guaranteed the full control of the safety data and continuous evaluation of the risk-benefit ratio. The LSO network participated in efficient regulatory compliance across multiple countries. In total, there were 1312 SAEs in EU-Response and 83 SAEs in c4c in the four trials. We present here the lessons learnt from our experience in four clinical trials. We managed heterogeneous European local requirements and implemented efficient communication with all trial teams. Our approach builds capacity for PV that can be used by multiple academic sponsors.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Terzić V, Levoyer L, Figarella M, et al. Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia. Br J Clin Pharmacol. 2023. PMID: 36680782. doi:10.1111/bcp.15669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。